Tango Therapeutics grants CFO 240,000-share option, 40,000 RSUs under inducement plan
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. TNGX | 0.00 |
- Tango Therapeutics granted inducement equity awards effective May 1, 2026, including a non-qualified stock option for 240,000 shares and 40,000 restricted stock units to CFO Matthew Gall.
- Separate inducement award issued to a new employee, covering a non-qualified stock option for 199,650 shares and 33,250 restricted stock units.
- Both option grants carry an exercise price of $20.98 per share, matching May 1 closing price; options run 10 years.
- Options vest over four years with 25% on first anniversary of start date, remainder in monthly installments over next three years; RSUs vest in roughly equal annual installments around May 10, 2027, May 10, 2028, May 9, 2029.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605041631PRIMZONEFULLFEED9712514) on May 04, 2026, and is solely responsible for the information contained therein.
